CA2920946A1 - Materials and methods relating to pancreatic cancer - Google Patents

Materials and methods relating to pancreatic cancer Download PDF

Info

Publication number
CA2920946A1
CA2920946A1 CA2920946A CA2920946A CA2920946A1 CA 2920946 A1 CA2920946 A1 CA 2920946A1 CA 2920946 A CA2920946 A CA 2920946A CA 2920946 A CA2920946 A CA 2920946A CA 2920946 A1 CA2920946 A1 CA 2920946A1
Authority
CA
Canada
Prior art keywords
tumor
pancreatic
protein
proteins
phosphorylation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2920946A
Other languages
English (en)
French (fr)
Inventor
Zen YOH
Nigel Heaton
Alberto Quaglia
David Britton
Malcolm Ward
Ian Pike
Vikram MITRA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proteome Sciences PLC
Kings College Hospital NHS Foundation Trust
Original Assignee
Electrophoretics Ltd
Kings College Hospital NHS Foundation Trust
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Electrophoretics Ltd, Kings College Hospital NHS Foundation Trust filed Critical Electrophoretics Ltd
Publication of CA2920946A1 publication Critical patent/CA2920946A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2920946A 2013-08-13 2014-08-13 Materials and methods relating to pancreatic cancer Abandoned CA2920946A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1314485.2A GB201314485D0 (en) 2013-08-13 2013-08-13 Materials and methods relating to pancreatic cancer
GB1314485.2 2013-08-13
PCT/GB2014/052475 WO2015022530A2 (en) 2013-08-13 2014-08-13 Materials and methods relating to pancreatic cancer

Publications (1)

Publication Number Publication Date
CA2920946A1 true CA2920946A1 (en) 2015-02-19

Family

ID=49262110

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2920946A Abandoned CA2920946A1 (en) 2013-08-13 2014-08-13 Materials and methods relating to pancreatic cancer

Country Status (7)

Country Link
US (1) US20160195536A1 (OSRAM)
EP (1) EP3033624A2 (OSRAM)
JP (1) JP2016535270A (OSRAM)
CN (1) CN105637367A (OSRAM)
CA (1) CA2920946A1 (OSRAM)
GB (1) GB201314485D0 (OSRAM)
WO (1) WO2015022530A2 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018532992A (ja) * 2015-09-09 2018-11-08 ソマロジック, インコーポレイテッドSomaLogic, Inc. 個別化薬物治療計画の開発方法、及びプロテオミックプロファイルに基づく標的薬物開発
US10617720B2 (en) * 2016-10-20 2020-04-14 Miltenyi Biotech, GmbH Chimeric antigen receptor specific for tumor cells
HUE055970T2 (hu) * 2016-12-20 2022-01-28 Treat4Life Ab Eljárás BRAF mutációk és vad típusú BRAF fehérje meghatározására tömegspektrometria segítségével
US11624082B2 (en) * 2018-06-21 2023-04-11 Universiteit Utrecht Holding B.V. Method for monitoring kinase activity in a sample
CN111066727B (zh) * 2019-12-20 2021-08-27 中国人民解放军陆军军医大学 在低氧性血睾屏障通透中作用机制的小鼠模型构建方法
IT202000016807A1 (it) * 2020-07-10 2022-01-10 Humanitas Mirasole Spa Peptidi associati a tumore e loro impiego
WO2022154037A1 (ja) * 2021-01-14 2022-07-21 公立大学法人福島県立医科大学 がんの予後バイオマーカー

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
DE69128350T2 (de) 1990-06-11 1998-03-26 Nexstar Pharmaceuticals Inc Nukleinsäureliganden
WO2003016861A2 (en) 2001-08-14 2003-02-27 President And Fellows Of Harvard College Absolute quantification of proteins and modified forms thereof by multistage mass spectrometry
WO2004055519A2 (en) * 2002-12-17 2004-07-01 Sinogenomax Co. Ltd. Specific markers for pancreatic cancer
CN1726395A (zh) * 2002-12-17 2006-01-25 北京诺赛基因组研究中心有限公司 胰腺癌的特异标记
US8346482B2 (en) * 2003-08-22 2013-01-01 Fernandez Dennis S Integrated biosensor and simulation system for diagnosis and therapy
DE102006056784A1 (de) * 2006-12-01 2008-06-05 Meyer, Helmut E., Prof.Dr. Biomarker für die Diagnose von Pankreaskrebs
GB0704764D0 (en) 2007-03-12 2007-04-18 Electrophoretics Ltd Isobarically labelled reagents and methods of their use
WO2009146545A1 (en) * 2008-06-05 2009-12-10 University Health Network Compositions and methods for classifying lung cancer and prognosing lung cancer survival
AU2010208394A1 (en) * 2009-01-27 2011-09-08 Hologic, Inc. Biomarkers for detection of neonatal sepsis in biological fluid
US20130023436A1 (en) * 2010-01-15 2013-01-24 Bryan William Jones Disease diagnosis and treatment using computational molecular phenotyping
TW201130830A (en) * 2010-02-01 2011-09-16 Ab Science Combined treatment of pancreatic cancer with gemcitabine and masitinib
CN102947706B (zh) * 2010-04-19 2018-04-13 生物标志物策略公司 预测药物敏感性、抗性和疾病进展的组合物和方法
BR112012030587A2 (pt) * 2010-06-01 2017-01-24 Ernst Moritz Arndt Universität métodos para diagnóstico de câncer pancreático, para identificar se um indivíduo precisa ou não de uma terapia contra câncer pancreático e para determinar se uma terapia contra câncer pancreático obtém sucesso, dispositivo para diagnóstico de câncer pancreático e uso de pelo menos um biomarcador
JP2013538042A (ja) * 2010-06-16 2013-10-10 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション エンドプラスミンに対する抗体およびその使用
US20140222443A1 (en) * 2011-06-07 2014-08-07 Kathleen Danenberg Molecular profiling for cancer

Also Published As

Publication number Publication date
CN105637367A (zh) 2016-06-01
GB201314485D0 (en) 2013-09-25
WO2015022530A3 (en) 2015-04-09
EP3033624A2 (en) 2016-06-22
US20160195536A1 (en) 2016-07-07
WO2015022530A2 (en) 2015-02-19
JP2016535270A (ja) 2016-11-10

Similar Documents

Publication Publication Date Title
Old et al. Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma
US20160195536A1 (en) Materials and Methods Relating to Pancreatic Cancer
Lucarelli et al. Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml
Lou et al. Cancer-specific production of N-acetylaspartate via NAT8L overexpression in non–small cell lung cancer and its potential as a circulating biomarker
Mikula et al. Integrating proteomic and transcriptomic high-throughput surveys for search of new biomarkers of colon tumors
Thinon et al. Global profiling of co-and post-translationally N-myristoylated proteomes in human cells
Tan et al. Cancer proteomics
JP6263474B2 (ja) ヌクレオソームアダクト検出法
Schrödter et al. Identification of the dopamine transporter SLC6A3 as a biomarker for patients with renal cell carcinoma
US10768182B2 (en) Method for detecting nucleosomes containing histone modifications and variants
Turay et al. Proteomic profiling of serum-derived exosomes from ethnically diverse prostate cancer patients
Sellers et al. Metabolic reprogramming and Notch activity distinguish between non-small cell lung cancer subtypes
Omenn et al. Alternative splice variants, a new class of protein cancer biomarker candidates: findings in pancreatic cancer and breast cancer with systems biology implications
EP2948775A2 (en) Compositions and methods for detecting neoplasia
Jiang et al. iTRAQ‐based quantitative proteomics approach identifies novel diagnostic biomarkers that were essential for glutamine metabolism and redox homeostasis for gastric cancer
Abe et al. Comprehensive characterization of the phosphoproteome of gastric cancer from endoscopic biopsy specimens
Chaker et al. Secretome proteins as candidate biomarkers for aggressive thyroid carcinomas
Duangkumpha et al. Discovery and qualification of serum protein biomarker candidates for cholangiocarcinoma diagnosis
Pavlou et al. Coupling proteomics and transcriptomics in the quest of subtype‐specific proteins in breast cancer
Wu et al. Next-generation novel noninvasive cancer molecular diagnostics platforms beyond tissues
Sun et al. From clinic to mechanism: Proteomics‐based assessment of angiogenesis in adrenal pheochromocytoma
Yang et al. Quantitative analysis of differential proteome expression in bladder cancer vs. normal bladder cells using SILAC method
Xiao et al. Cyclin B2 overexpression promotes tumour growth by regulating jagged 1 in hepatocellular carcinoma
Cui et al. TRIM37 augments AP-2γ transcriptional activity and cellular localization via K63-linked ubiquitination to drive breast cancer progression
D’Alessandro et al. Proteomics and metabolomics in cancer drug development

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20200831